tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Editas Medicine (EDIT) and Genenta Science SpA Sponsored ADR (GNTA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Siemens Healthineers AG (SEMHFResearch Report), Editas Medicine (EDITResearch Report) and Genenta Science SpA Sponsored ADR (GNTAResearch Report) with bullish sentiments.

Siemens Healthineers AG (SEMHF)

Berenberg Bank analyst Odysseas Manesiotis maintained a Buy rating on Siemens Healthineers AG yesterday and set a price target of EUR75.00. The company’s shares closed last Thursday at $55.45, equals to its 52-week low of $55.45.

According to TipRanks.com, Manesiotis is ranked #7388 out of 7897 analysts.

Currently, the analyst consensus on Siemens Healthineers AG is a Moderate Buy with an average price target of $72.53, representing a 32.3% upside. In a report issued on April 27, J.P. Morgan also maintained a Buy rating on the stock with a EUR71.10 price target.

See the top stocks recommended by analysts >>

Editas Medicine (EDIT)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Editas Medicine, with a price target of $60.00. The company’s shares closed last Wednesday at $15.81, close to its 52-week low of $12.90.

According to TipRanks.com, Livshits is a 5-star analyst with an average return of 27.3% and a 39.4% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics, and Crispr Therapeutics AG.

Currently, the analyst consensus on Editas Medicine is a Hold with an average price target of $29.00, which is a 102.1% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $39.00 price target.

Genenta Science SpA Sponsored ADR (GNTA)

Maxim Group analyst Naureen Quibria reiterated a Buy rating on Genenta Science SpA Sponsored ADR yesterday and set a price target of $21.00. The company’s shares closed last Wednesday at $5.60, close to its 52-week low of $5.11.

According to TipRanks.com, Quibria has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -23.0% and a 20.3% success rate. Quibria covers the Healthcare sector, focusing on stocks such as Fennec Pharmaceuticals, Ayala Pharmaceuticals, and Kazia Therapeutics.

Currently, the analyst consensus on Genenta Science SpA Sponsored ADR is a Moderate Buy with an average price target of $21.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SEMHF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed